SELLAS Life Sciences is a long idea based on its WT1-targeting cancer drug GPS and the Phase 3 REGAL study.
SLS — LONG The author argues that SLS's leukemia drug GPS targets WT1, a well-known cancer target across many cancers, and has shown real immune responses and clinical outcomes. The flexibility of GPS could open other WT1-expressing cancers. The Phase 3 REGAL study is expected to progress and the recent warrant-related dip is seen as an entry opportunity.
I REALLY think this thing is going to explode as the Phase 3 REGAL study progresses. It dipped after warrants were sold off, so now is a great time to get in.
This Reddit post, published January 12, 2026, features u/BenLomondBitch discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/BenLomondBitch · Tickers: SLS